Product Description
BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis. (Sourced from: https://clinicaltrials.gov/study/NCT07105488)
Mechanisms of Action: IL1RAP Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bluefin Biomedicine, Inc.
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Canada, Czech Republic, Germany, Poland, Spain, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hidradenitis Suppurativa
Phase 2: Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07105488 |
COMPASS 2-AD | P2 |
Active, not recruiting |
Dermatitis, Atopic |
2027-02-28 |
70% |
2026-07-31 |
|
NCT07287644 |
COMPASS 2-HS | P3 |
Recruiting |
Hidradenitis Suppurativa |
2027-08-01 |
10% |
2026-05-30 |
Primary Endpoints|Treatments |
2025-521624-30-00 |
CL-BFB759-002 | P2 |
Not yet recruiting |
Dermatitis, Atopic |
2027-12-31 |
|||
2025-522440-41-00 |
CL-BFB759-003 | P2 |
Not yet recruiting |
Hidradenitis Suppurativa |
2027-08-01 |
Recent News Events
Date |
Type |
Title |
|---|